For years, a woman with early breast cancer and a middling test score faced a coin-flip question. Chemotherapy or no chemotherapy? Nobody had hard proof either way.
The TAILORx trial supplied it. Dr. Joseph Sparano, the lead author, released the results at the ASCO annual meeting in Chicago in June 2018, with simultaneous publication in the New England Journal of Medicine. He works in New York, where he is the associate director of clinical research for the Albert Einstein Cancer Center and Montefiore, and he is vice chair of the ECOG-ACRIN research group. That group designed and led the study, and the National Cancer Institute supported it.
How the trial worked
TAILORx opened in 2006. It enrolled 10,273 women at 1,182 sites spread over six countries, from Peru to Ireland. Their cancer was hormone receptor positive and HER2 negative, and it had not reached the axillary lymph nodes. Each woman’s tumor was scored from 0 to 100 on the Oncotype DX test, which looks at the activity of 21 genes tied to recurrence.
Earlier evidence already pointed the way at the extremes. Women scoring 0 to 10 got hormone therapy alone. Those scoring 26 or higher got hormone therapy plus chemotherapy. The open question sat in the middle. Women with scores of 11 to 25 were assigned by chance to hormone therapy alone or to hormone therapy with chemotherapy.
What it found
The two groups did almost the same. After five years, 92.8 percent of the hormone-only group and 93.1 percent of the chemotherapy group had avoided death, recurrence or a second cancer. At nine years the figures were 83.3 percent and 84.3 percent. None of the gaps was statistically significant. Overall survival told the same story: 98.0 and 98.1 percent at five years, 93.9 and 93.8 percent at nine.
“These data confirm that using a 21-gene expression test to assess the risk of cancer recurrence can spare women unnecessary treatment if the test indicates that chemotherapy is not likely to provide benefit,” Sparano said.
Jeffrey Abrams of the National Cancer Institute said the intermediate group had been the uncertain one: oncologists could advise women at high and low risk, but not those in between.
The authors estimated that roughly 70 percent of women who have this type of cancer could skip chemotherapy. That covered women older than 50 with a score of 11 to 25 (45 percent), women of any age scoring 0 to 10 (16 percent), and women 50 or younger scoring 11 to 15 (8 percent). Chemotherapy might still be considered for the other 30 percent.
The high-risk group
Women scoring 26 to 100 did not escape. Even with chemotherapy and hormone therapy, 13 percent had a distant recurrence, which the authors said showed a need for better treatments. A 2019 follow-up in JAMA Oncology looked at 1,389 of them and put freedom from distant recurrence at 93% at five years, far better than expected with hormone therapy alone. Sparano said the result confirmed that the test picks out the minority who gain a significant benefit from adding chemotherapy.
Sources
- TAILORx trial finds most women with early breast cancer do not benefit from chemotherapy (NCI)
- TAILORx: New data on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years (EurekAlert)





